Article Text

Download PDFPDF

L1 TGF-beta blocks type I IFN release and tumor rejection in spontaneous mammary tumors
  1. N Bercovici1,
  2. MV Guérin1,
  3. F Regnier1,
  4. JM Weiss1,
  5. V Feuillet1,
  6. L Vimeux1,
  7. G Altan-Bonnet2,
  8. E Donnadieu1 and
  9. A Trautmann1
  1. 1Cochin Institute, 75014, France
  2. 2National Cancer Institute, Bethesda, MD, USA


Background Activation of the STimulator of INterferon Genes (STING) by DMXAA (5,6-dimethylxanthenone-4-acetic acid) can induce a strong production of IFNα/β and the rejection of transplanted primary tumors. However, the efficacy of such therapeutic approach for the treatment of spontaneous tumors had still to be evaluated.

Material and Methods We have tested whether the injection of DMXAA or other STING agonists and TLR4 agonist, could lead to the regression of spontaneous MMTV-PyMT mammary tumors. We also characterized, in time and space, the early signaling events triggered downstream STING and the distribution of infiltrating immune cells in the tumor microenvironment by fluorescence imaging.

Results We show that spontaneous MMTV-PyMT mammary tumors are resistant to immunotherapeutic intervention. We demonstrate that TGFβ, abundant in spontaneous tumors, is a key molecule limiting this IFN-induced-tumor regression by DMXAA. Mechanistically, we found that TGFβ blocks the phosphorylation of IRF3 and the ensuing IFNα/β production by tumor infiltrating macrophages. Finally, blocking TGFβ restores the production of IFNα by activated MHCII+ tumor-associated macrophages, and enables tumor regression induced by STING activation.

Conclusions Based on these findings, we propose that the efficacy of many cancer therapies, which are type I IFN-dependent, should be greatly improved by combination with TGFβ blockade.

Disclosure Information N. Bercovici: None. M.V. Guérin: None. F. Regnier: None. J.M. Weiss: None. V. Feuillet: None. L. Vimeux: None. G. Altan-Bonnet: None. E. Donnadieu: None. A. Trautmann: None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.